Clinical Trial Update: Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial update on SPD489 for maintenance of efficacy in adults with moderate to severe binge eating disorder has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• SPD489

Snippet

Sponsor: Shire | Conditions: Binge Eating Disorder | Phase 3 | Status: COMPLETED | Results posted: 2016-04-01